Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-(dibenzo[b,d]thiophen-3-ylsulfonyl)-L-valine is an experimental small molecule compound belonging to the class of valine derivatives. It acts as a selective inhibitor of macrophage metalloelastase, also known as matrix metalloproteinase 12 (MMP12). Macrophage metalloelastase is involved in tissue injury and remodeling, with significant elastolytic activity. Inhibition of this enzyme has been explored for potential therapeutic applications in diseases involving excessive tissue degradation or inflammation, such as chronic obstructive pulmonary disease (COPD) and asthma. However, there are no approved indications or clinical trials reported for this compound[1][2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-(dibenzo[b,d]thiophen-3-ylsulfonyl)-L-valine.